Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Krystal Biotech stock

KRYS
US5011471027
A2JH2F

Price

178.31
Today +/-
+2.52
Today %
+1.51 %
P

Krystal Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Krystal Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Krystal Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Krystal Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Krystal Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Krystal Biotech Stock Price History

DateKrystal Biotech Price
11/18/2024178.31 undefined
11/18/2024175.64 undefined
11/15/2024170.74 undefined
11/14/2024177.39 undefined
11/13/2024187.51 undefined
11/12/2024187.22 undefined
11/11/2024195.87 undefined
11/8/2024199.61 undefined
11/7/2024185.45 undefined
11/6/2024183.09 undefined
11/5/2024174.41 undefined
11/4/2024170.85 undefined
11/1/2024176.39 undefined
10/31/2024172.53 undefined
10/30/2024175.53 undefined
10/29/2024176.22 undefined
10/28/2024176.89 undefined
10/25/2024175.51 undefined
10/24/2024174.98 undefined
10/23/2024172.75 undefined
10/22/2024175.20 undefined
10/21/2024178.98 undefined

Krystal Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Krystal Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Krystal Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Krystal Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Krystal Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Krystal Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Krystal Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Krystal Biotech’s growth potential.

Krystal Biotech Revenue, EBIT and net profit per share

DateKrystal Biotech RevenueKrystal Biotech EBITKrystal Biotech Net Income
2029e1.1 B undefined0 undefined371.97 M undefined
2028e953.6 M undefined549.17 M undefined424.48 M undefined
2027e802.83 M undefined434.36 M undefined332.59 M undefined
2026e667.81 M undefined332.82 M undefined264.18 M undefined
2025e471.03 M undefined211.63 M undefined172.93 M undefined
2024e296.92 M undefined66.85 M undefined82.14 M undefined
202350.7 M undefined-97.23 M undefined10.93 M undefined
20220 undefined-120.2 M undefined-139.98 M undefined
20210 undefined-68.28 M undefined-69.57 M undefined
20200 undefined-33 M undefined-32.17 M undefined
20190 undefined-22.08 M undefined-19.09 M undefined
20180 undefined-11.92 M undefined-10.89 M undefined
20170 undefined-4.77 M undefined-7.92 M undefined
20160 undefined-1.14 M undefined-1.15 M undefined

Krystal Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000.050.30.470.670.80.951.1
--------492.0059.1241.6120.2418.8315.84
-------94.0015.889.987.055.864.934.26
000000047000000
-1-7-10-19-32-69-1391082172264332424371
-600.0042.8690.0068.42115.63101.45-107.19720.00109.7653.4925.7627.71-12.50
8.6810.3111.215.918.7922.225.4927.75000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Krystal Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Krystal Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
1.949.6111.8193.7271.3438.1379.2532.18
000000042.04
00000000
00000006.99
0.20.30.92.23.84.24.66.71
2.149.9112.7195.9275.1442.3383.8587.91
00.2311.234.2119.6169.7168.23
0000.5064.44.661.95
00000000
00000000
00000000
000.51.51.60.10.30.26
00.23.513.235.8184.1174.6230.45
2.150.1116.2209.1310.9626.4558.4818.36
               
1.40000000
00.060.130.240.360.730.81.05
-1.2-9.1-20-39-71.2-140.8-280.8-269.83
00000-200-700637.72
00000000
0.249.4113.2203292.1593.5522.2778.64
00.20.90.72.18.444.13
00.31.52.55.717.224.624.47
00.10.20.17.70.20.34.49
00000000
00000000
00.62.63.315.525.828.933.09
1.80000000
00000000
000.32.83.377.46.62
1.800.32.83.377.46.62
1.80.62.96.118.832.836.339.71
250116.1209.1310.9626.3558.5818.35
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Krystal Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Krystal Biotech's financial health and stability.

Assets

Krystal Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Krystal Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Krystal Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Krystal Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-1-7-10-19-32-69-13910
00011245
00000000
000-2022-137
03126326573
00000000
00000000
-1-3-9-18-26-47-100-88
00-2-6-14-68-52-11
00-10-4-11-226-11482
00-813-158-6194
00000000
12000000
1497310711835536203
3517310711834735202
------7.00--
00000000
14754838072-179196
-1.33-4.1-11.68-25.09-40.92-116.28-153.55-100.6
00000000

Krystal Biotech stock margins

The Krystal Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Krystal Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Krystal Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Krystal Biotech's sales revenue. A higher gross margin percentage indicates that the Krystal Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Krystal Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Krystal Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Krystal Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Krystal Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Krystal Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Krystal Biotech Margin History

Krystal Biotech Gross marginKrystal Biotech Profit marginKrystal Biotech EBIT marginKrystal Biotech Profit margin
2029e93.9 %0 %33.69 %
2028e93.9 %57.59 %44.51 %
2027e93.9 %54.1 %41.43 %
2026e93.9 %49.84 %39.56 %
2025e93.9 %44.93 %36.71 %
2024e93.9 %22.52 %27.66 %
202393.9 %-191.77 %21.56 %
202293.9 %0 %0 %
202193.9 %0 %0 %
202093.9 %0 %0 %
201993.9 %0 %0 %
201893.9 %0 %0 %
201793.9 %0 %0 %
201693.9 %0 %0 %

Krystal Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Krystal Biotech earnings per share therefore indicates how much revenue Krystal Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Krystal Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Krystal Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Krystal Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Krystal Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Krystal Biotech Revenue, EBIT and net profit per share

DateKrystal Biotech Sales per ShareKrystal Biotech EBIT per shareKrystal Biotech Earnings per Share
2029e38.39 undefined0 undefined12.93 undefined
2028e33.16 undefined0 undefined14.76 undefined
2027e27.91 undefined0 undefined11.56 undefined
2026e23.22 undefined0 undefined9.19 undefined
2025e16.38 undefined0 undefined6.01 undefined
2024e10.32 undefined0 undefined2.86 undefined
20231.83 undefined-3.5 undefined0.39 undefined
20220 undefined-4.72 undefined-5.49 undefined
20210 undefined-3.08 undefined-3.13 undefined
20200 undefined-1.76 undefined-1.71 undefined
20190 undefined-1.39 undefined-1.2 undefined
20180 undefined-1.06 undefined-0.97 undefined
20170 undefined-0.46 undefined-0.77 undefined
20160 undefined-0.13 undefined-0.13 undefined

Krystal Biotech business model

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech is one of the most popular companies on Eulerpool.com.

Krystal Biotech SWOT Analysis

Strengths

Krystal Biotech Inc possesses several unique strengths that contribute to its competitive advantage in the biotech industry. Firstly, the company has a strong research and development team comprising highly skilled scientists and experts. Their expertise allows Krystal Biotech to continuously innovate and develop cutting-edge gene therapy products.

Another key strength of Krystal Biotech is its proprietary technology platforms. The company's advanced gene delivery system enables efficient and targeted delivery of genetic therapies, offering potential breakthrough treatments for various diseases. This technology provides a significant advantage over competitors.

Weaknesses

Despite its strengths, Krystal Biotech Inc faces some weaknesses that could impact its performance. One notable weakness is the company's relatively small scale compared to larger biotech firms. Limited resources and infrastructure may hinder the company's ability to quickly scale up production or compete on the same level as industry giants.

Additionally, as a relatively young company, Krystal Biotech may lack the extensive market experience and established partnerships that larger competitors possess. This could make it more challenging for the company to penetrate new markets or negotiate favorable business deals.

Opportunities

Krystal Biotech Inc operates in an industry with vast opportunities for growth. The increasing demand for gene therapy products and personalized medicine presents a significant opportunity for the company to expand its market presence and generate substantial revenue.

Furthermore, Krystal Biotech can explore strategic collaborations with academic institutions and other biotech companies to leverage shared resources, expertise, and enhance research capabilities. Such partnerships can lead to accelerated development of new therapies, paving the way for additional revenue streams and market collaborations.

Threats

Despite the opportunities, Krystal Biotech also faces certain threats that could impact its competitive position. One such threat is the highly regulated nature of the biotech industry. Stringent regulatory processes and compliance requirements can result in delays or even failure in obtaining necessary approvals for product commercialization.

Additionally, potential competition from established biotech companies and emerging startups poses a threat to Krystal Biotech's market share. The industry's rapid pace of innovation means that competitors may quickly develop similar gene therapies, potentially eroding the company's competitive advantage.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Krystal Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Krystal Biotech historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Krystal Biotech shares outstanding

The number of shares was Krystal Biotech in 2023 — This indicates how many shares 27.752 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Krystal Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Krystal Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Krystal Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Krystal Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Krystal Biotech.

Krystal Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.92 0.91  (-0.73 %)2024 Q3
6/30/20240.59 0.53  (-10.41 %)2024 Q2
3/31/20240.15 0.03  (-80.01 %)2024 Q1
12/31/2023-0.43 0.3  (169.2 %)2023 Q4
9/30/2023-0.29 -0.69  (-136.54 %)2023 Q3
6/30/2023-0.75 -1.25  (-66.36 %)2023 Q2
3/31/2023-1.47 -1.76  (-19.95 %)2023 Q1
12/31/2022-1.35 -1.25  (7.28 %)2022 Q4
9/30/2022-1.24 -1.17  (5.76 %)2022 Q3
6/30/2022-1.04 -1.1  (-6.18 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Krystal Biotech stock

Eulerpool World ESG Rating (EESG©)

46/ 100

🌱 Environment

19

👫 Social

85

🏛️ Governance

35

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Krystal Biotech shareholders

%
Name
Stocks
Change
Date
14.86890 % Fidelity Management & Research Company LLC4,276,29639,6196/30/2024
12.78486 % BlackRock Institutional Trust Company, N.A.3,676,9272,055,3596/30/2024
9.96314 % The Vanguard Group, Inc.2,865,400436,3576/30/2024
8.45967 % Avoro Capital Advisors LLC2,433,000-122,5556/30/2024
5.91885 % Krishnan (Krish S)1,702,262-25,0009/12/2024
5.53158 % Krishnan (Suma M)1,590,882-25,0009/12/2024
5.05150 % State Street Global Advisors (US)1,452,811119,9369/30/2024
3.55034 % Redmile Group, LLC1,021,078-487,1726/30/2024
3.43693 % Frazier Life Sciences Management, L.P.988,46006/30/2024
3.05340 % Capital World Investors878,158781,0116/30/2024
1
2
3
4
5
...
10

Krystal Biotech Executives and Management Board

Mr. Krish Krishnan(58)
Krystal Biotech Chairman of the Board, President, Chief Executive Officer (since 2016)
Compensation 3.26 M
Ms. Suma Krishnan(58)
Krystal Biotech Founder, Chief Operating Officer, Director, President - Research and Development (since 2016)
Compensation 2.98 M
Ms. Kathryn Romano(42)
Krystal Biotech Chief Accounting Officer
Compensation 2.72 M
Dr. Everett Sutherland(53)
Krystal Biotech Independent Director
Compensation 879,694
Mr. Daniel Janney(57)
Krystal Biotech Lead Independent Director
Compensation 385,856
1
2
3

Most common questions regarding Krystal Biotech

What values and corporate philosophy does Krystal Biotech represent?

Krystal Biotech Inc represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing and delivering advanced gene therapies to treat rare skin diseases. With a vision to transform lives, Krystal Biotech focuses on providing effective and safe solutions that address unmet medical needs. Their corporate philosophy revolves around promoting patient-centric care, scientific rigor, and ethical practices. By leveraging cutting-edge technology and scientific expertise, Krystal Biotech strives to enhance the quality of life for individuals affected by genetic skin disorders.

In which countries and regions is Krystal Biotech primarily present?

Krystal Biotech Inc is primarily present in the United States.

What significant milestones has the company Krystal Biotech achieved?

Krystal Biotech Inc has achieved several significant milestones. One of the notable achievements includes the successful completion of the phase 2 clinical trial for their gene therapy product, known as KB103. This product aims to treat a rare skin disorder called dystrophic epidermolysis bullosa (DEB). Additionally, the company has also achieved positive results in pre-clinical trials for other gene therapy candidates, showcasing their potential to address various genetic disorders. Krystal Biotech Inc has received several grants and awards for their innovative research and development efforts. These achievements highlight the promising growth and potential of Krystal Biotech Inc in the field of gene therapy.

What is the history and background of the company Krystal Biotech?

Krystal Biotech Inc, headquartered in Pittsburgh, Pennsylvania, is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients suffering from rare genetic diseases. Founded in 2015, Krystal Biotech is driven by a mission to deliver potentially curative therapies that address the unmet medical needs of patients worldwide. Leveraging its proprietary Skin TARgeted Delivery platform, the company aims to develop innovative gene therapies for dermatological conditions, starting with its lead product candidate, KB105. Through strategic collaborations, Krystal Biotech strives to revolutionize the treatment landscape by advancing gene therapies to provide hope for patients and their families.

Who are the main competitors of Krystal Biotech in the market?

The main competitors of Krystal Biotech Inc in the market include companies such as Regenxbio Inc, bluebird bio Inc, and Sangamo Therapeutics Inc. These companies have a similar focus on gene therapy and are actively engaged in the development and commercialization of innovative treatments for genetic diseases. Krystal Biotech Inc competes with these companies in terms of research, development, and market adoption of gene therapy products.

In which industries is Krystal Biotech primarily active?

Krystal Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Krystal Biotech?

Krystal Biotech Inc is a biopharmaceutical company specializing in gene therapies. Their business model focuses on developing and commercializing innovative treatments to address severe dermatological diseases. By harnessing the power of gene therapy, Krystal Biotech aims to provide targeted and sustainable solutions for patients, offering potential long-term benefits. With a strong emphasis on cutting-edge research and development, they strive to revolutionize the treatment landscape by creating novel therapies that address unmet medical needs. Krystal Biotech Inc's business model is driven by a commitment to scientific excellence and a passion for improving the lives of patients suffering from dermatological conditions.

What is the P/E ratio of Krystal Biotech 2024?

The Krystal Biotech P/E ratio is 60.25.

What is the P/S ratio of Krystal Biotech 2024?

The Krystal Biotech P/S ratio is 16.67.

What is the Quality Investing of Krystal Biotech?

The Quality Investing for Krystal Biotech is 3/10.

What is the revenue of Krystal Biotech 2024?

The expected Krystal Biotech revenue is 296.92 M USD.

How high is the profit of Krystal Biotech 2024?

The expected Krystal Biotech profit is 82.14 M USD.

What is the business model of Krystal Biotech

Krystal Biotech Inc is a biotechnology company focused on developing gene therapy products for rare dermatology and genetic diseases. The company aims to develop innovative therapies that improve the lives of patients with rare diseases. The business model is based on the development and commercialization of gene therapy products. Krystal Biotech uses a proprietary gene therapy platform called HSV-1 vector to develop therapies for serious and rare dermatological conditions such as Epidermolysis bullosa, Netherton syndrome, and Heidelberg syndrome. The company's gene therapy products utilize the HSV-1 vector's ability to introduce DNA into rapidly dividing cells, such as skin cells, to replace the defective gene causing the disease and restore normal functioning of the affected cells. Krystal Biotech focuses on developing gene therapies for severe and rare diseases where effective treatments are often lacking. The company has several gene therapy products in development, including KB103 for the treatment of Epidermolysis bullosa, KB105 for the treatment of Netherton syndrome, and KB104 for the treatment of Heidelberg syndrome. KB103 is currently in phases 1 and 2 of clinical development and has the potential to become the first approved gene therapy product for treating Epidermolysis bullosa. Krystal Biotech also places a strong emphasis on collaboration with other companies and stakeholders in the biotechnology industry. The company has entered into a collaboration agreement with the international pharmaceutical company Bayer to develop a gene therapy platform for the treatment of serious eye diseases. In summary, Krystal Biotech's business model is based on the development and commercialization of gene therapy products for rare dermatological and genetic diseases. The company aims to improve the lives of patients with severe and rare diseases and seeks partnerships and alliances with other biotechnology companies and stakeholders in the industry to achieve this goal.

What is the Krystal Biotech dividend?

Krystal Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Krystal Biotech pay dividends?

The dividend cannot currently be calculated for Krystal Biotech or the company does not pay out a dividend.

What is the Krystal Biotech ISIN?

The ISIN of Krystal Biotech is US5011471027.

What is the Krystal Biotech WKN?

The WKN of Krystal Biotech is A2JH2F.

What is the Krystal Biotech ticker?

The ticker of Krystal Biotech is KRYS.

How much dividend does Krystal Biotech pay?

Over the past 12 months, Krystal Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Krystal Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Krystal Biotech?

The current dividend yield of Krystal Biotech is .

When does Krystal Biotech pay dividends?

Krystal Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Krystal Biotech?

Krystal Biotech paid dividends every year for the past 0 years.

What is the dividend of Krystal Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Krystal Biotech located?

Krystal Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Krystal Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Krystal Biotech from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Krystal Biotech pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Krystal Biotech in the year 2023?

In the year 2023, Krystal Biotech distributed 0 USD as dividends.

In which currency does Krystal Biotech pay out the dividend?

The dividends of Krystal Biotech are distributed in USD.

All fundamentals about Krystal Biotech

Our stock analysis for Krystal Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Krystal Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.